Quick Takeaways
- Squadron Capital Management LLC filed SCHEDULE 13G for Zentalis Pharmaceuticals, Inc. Common Stock,$0.001 par value per share (ZNTL).
- Disclosed ownership: 5.1%.
- Date of event: 24 Feb 2026.
Squadron Capital Management LLC - 24 Feb 2026 SCHEDULE 13G Report for Zentalis Pharmaceuticals, Inc. Common Stock,$0.001 par value per share (ZNTL)
- Filing Manager
- Squadron Capital Management LLC
- Reporting Manager
- Squadron Master Fund LP
- Symbol
- ZNTL
- Shares outstanding
- 72,096,078 shares
- Disclosed Ownership
- 3,676,900 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13G
- Filing time
- 03 Mar 2026, 16:05:37 UTC
- Date of event
- 24 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Squadron Capital Management LLC disclosed 5.1% ownership in Zentalis Pharmaceuticals, Inc. Common Stock,$0.001 par value per share (ZNTL) on 24 Feb 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Mar 2026, 16:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Squadron Master Fund LP | 5.1% | 3,676,900 | 0 | 3,676,900 | /s/ Matthew Sesterhenn | Partner, Squadron Partners LLC, its General Partner | |
| Squadron Capital Management LLC | 5.1% | 3,676,900 | 0 | 3,676,900 | /s/ Matthew Sesterhenn | Partner | |
| Matthew Sesterhenn | 5.1% | 3,676,900 | 0 | 3,676,900 | /s/ Matthew Sesterhenn | Matthew Sesterhenn | |
| William Blank | 5.1% | 3,676,900 | 0 | 3,676,900 | /s/ William Blank | William Blank |